Biomedical Engineering Reference
In-Depth Information
76. Gepp MM, Hutter MC (2006) Determination of hERG channel blockers using a decision
tree. Bioorg Med Chem 14:5325-5332
77. Hidaka S, Yamasaki H, Ohmayu Y et al (2010) Nonlinear classification of hERG channel
inhibitory activity by unsupervised classification method. J Toxicol Sci 35:393-399
78. Papadatos G, Alkarouri M, Gillet VJ et al (2010) Lead optimization using matched molecular
pairs: inclusion of contextual information for enhanced prediction of HERG inhibition,
solubility, and lipophilicity. J Chem Inf Model 50:1872-1886
79. Doyle DA, Morais Cabral J, Pfuetzner RA et al (1998) The structure of the potassium
channel: molecular basis of K+ conduction and selectivity. Science 280:69-77
80. Zhou Y, Morais-Cabral JH, Kaufman A et al (2001) Chemistry of ion coordination and
hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature 414:43-48
81. Zhou Y, MacKinnon R (2003) The occupancy of ions in the K+ selectivity filter: charge
balance and coupling of ion binding to a protein conformational change underlie high
conduction rates. J Mol Biol 333:965-975
82. Kuo A, Gulbis JM, Antcliff JF et al (2003) Crystal structure of the potassium channel
KirBac1.1 in the closed state. Science 300:1922-1926
83. Jiang Y, Lee A, Chen J et al (2002) Crystal structure and mechanism of a calcium-gated
potassium channel. Nature 417:515-522
84. Jiang Y, Lee A, Chen J et al (2003) X-ray structure of a voltage-dependent K+ channel.
Nature 423:33-41
85. Jalaie M, Holsworth DD (2005) QT interval prolongation: and the beat goes on. Mini Rev
Med Chem 5:1083-1091
86. Recanatini M, Poluzzi E, Masetti M et al (2005) QT prolongation through hERG K(+)
channel blockade: current knowledge and strategies for the early prediction during drug
development. Med Res Rev 25:133-166
87. Aronov AM (2005) Predictive in silico modeling for hERG channel blockers. Drug Discov
Today 10:149-155
88. Duncan RS, Ridley JM, Dempsey CE et al (2006) Erythromycin block of the HERG K+
channel: accessibility to F656 and Y652. Biochem Biophys Res Commun 341:500-506
89. Rajamani R, Tounge BA, Li J et al (2005) A two-state homology model of the hERG K+
channel: application to ligand binding. Bioorg Med Chem Lett 15:1737-1741
90. Yi H, Cao Z, Yin S et al (2007) Interaction simulation of hERG K+ channel with its specific
BeKm-1 peptide: insights into the selectivity of molecular recognition. J Proteome Res 6:
611-620
91. Masetti M, Cavalli A, Recanatini M (2008) Modeling the hERG potassium channel in a
phospholipid bilayer: molecular dynamis and drug docking studies. J Comput Chem 29:
795-808
92. Du L, Li M, You Q et al (2007) A novel structure-based virtual screening model for the
hERG channel blockers. Biochem Biophys Res Commun 355:889-894
93. Singleton DH, Boyd H, Steidl-Nichols JV et al (2007) Fluorescently labeled analogues of
dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-
related gene (hERG) channel. J Med Chem 50:2931-2941
94. Stansfeld PJ, Gedeck P, Gosling M et al (2007) Drug block of the hERG potassium channel:
insight from modeling. Proteins 68:568-580
95. Hosaka Y, Iwata M, Kamiya N et al (2007) Mutational analysis of block and facilitation of
HERG current by a class III anti-arrhythmic agent, nifekalant. Channels (Austin) 1:198-208
96. Tseng GN, Sonawane KD, Korolkova YV et al (2007) Probing the outer mouth structure of
the HERG channel with peptide toxin footprinting and molecular modeling. Biophys J
92:3524-3540
97. Choe H, Nah KH, Lee SN et al (2006) A novel hypothesis for the binding mode of HERG
channel blockers. Biochem Biophys Res Commun 344:72-78
